Working with the teams developing the next generation of neurology drugs. ALS drugs. FTD drugs. schizophrenia drugs. Parkinson's drugs.

Verge has signed partnerships with leading pharmaceutical and biotech companies, totaling more than $1.6 billion in announced deal value. We believe that models trained on our human datasets can help with nearly every problem in neuroscience drug development, from uncovering new targets grounded in human biology to identifying patients most likely to respond to investigational CNS drugs.

Engagement models range from full target discovery campaigns to focused human-relevance assessments on a single asset. Drug developers can engage with CONVERGE today in three places in the pipeline that can have an outsized impact on translational success:

1. Novel target discovery: surface new drug targets grounded directly in human disease biology.
2. Program enablement: de-risk the path from target to clinic.
3. Clinical trial optimization: match the right drug to the right patient with the right biomarkers.